Guidance Ref. No.
Question
Answer
Rationale
MAIN FLOWCHART
WHEN TO FILE A 510(K) AFTER CHANGE TO A LEGALLY MARKETED DEVICE
1
Change made with intent to significantly improve the safety or effectiveness of the device?
Yes -New
510K / No – See Question 2
No
Label updates Only
2
Labeling change?
Yes -See Chart A / No – See Question 3
Yes
See Below
3
Technology, engineering or performance change?
Yes -See Chart B / No – See Question 3
No
No Changes
4
Materials change?
Yes -See Chart C / No – Documentation
No
No Changes
FLOWCHART A – LABELING CHANGES?
A1
Does the change affect the indications for use statement?
Yes – See A1.1 / No – See Question A2
No
Not Changed
A2
Does the change add or delete a contraindication?
Yes -New 510K / No – See Question A3
No
Not Changed
A3
Is this a change in the warnings or precautions?
Yes – See A1.1 / No – See Question A4
No
Not Changed
A4
Could the change affect the directions for use?
Yes – See A1.1 / No – Documentation
No
Not Changed
A1.1
Is it a change from a device labeled for single use only to a device labeled as reusable?
Yes – New 510K / No – See Question A1.2
No
Not Changed
A1.2
Is it a change from Rx to over the counter OTC use?
Yes – New 510K / No – See Question A1.3
No
Not Changed
A1.3
Is it a change to the device name or to solely improve readability or clarity?
Yes – Documentation / No – See Question A1.4
No
Not Changed
A1.4
Does the change describe a new disease, condition, or pt pop that the device is intended in diagnosing, treating, preventing, curing or mitigating?
Yes – Documentation / No – See Question A1.5
No
Not Changed
A1.5
Does a risk-based assessment identify any new risks or significantly modified existing risks?
Yes – 510K see chart / No – Documentation
No
FLOWCHART B – TECHNOLOGY, ENGINEERING, PERFORMANCE CHANGES?
B1
Is the device an IVD?
Yes – See Chart D / No – See Question B2
N/A
B2
Is it a control mechanism, operating principle, or energy type change?
Yes – New 510K / No – See Question B3
N/A
B3
Is it a change in sterilization, cleaning, or disinfection?
Yes – See Question B3.1 / No – See Question B4
N/A
B3.1
Is it a change to a Cat. B or novel method, does it lower the SAL, or is it a change to how the device is provided?
Yes – New 510k / No – See Question B3.2
N/A
B3.2
Could the change significantly affect performance/ biocompatibility?
Yes – New 510k / No – Documentation
N/A
B4
Is there a change in packaging or expiration dating?
Yes – See Question B4.1 / No – See Question B5
N/A
B4.1
Is the same method or protocol, described in previous 510(k), used to support change?
Yes – Documentation / No – new 510k
N/A
B5
Is it any other change in design (e.g., dimensions, performance specifications, wireless communications, components or accessories, patient/user interface)?
Yes – See Question B5.1 / No – Documentation
N/A
B5.1
Does the change significantly affect the use of the device?
Yes – new 510k / No – See Question B5.2
N/A
B5.2
Does a risk assessment identify any new or significantly modified risks?
Yes – new 510k / No – See Question B5.3
N/A
B5.3
Is clinical data necessary?
Yes – new 510k / No – See Question B5.4
N/A
B5.4
Any unexpected issues from V&V activities?
Yes – new 510k / No – Documentation
N/A
FLOWCHART C – MATERIAL CHANGES?
C1
Is the device an IVD?
Yes – See Chart D / No – See Question C2
N/A
C2
Change in material type, formulation, chemical composition, or the material’s processing?
Yes – See Question C3 / No – Documentation
N/A
C3
Will the changed material directly or indirectly contact body tissues or fluids?
Yes – See Question C4 / No – See Question C5
N/A
C4
Does a risk assessment identify any new or increased biocompatibility concerns?
Yes – See Question C4.1 / No – See Question C5
N/A
C4.1
Has the manufacturer used the same material in a similar legally marketed device (including formulation, processing, type and duration of contact, etc.)?
Yes – See Question C5 / No – New 510k
N/A
C5
Could the change affect performance specifications?
Yes – See Question B5 / No – Documentation
N/A
SOFTWARE CHANGES?
1
Is the change made solely to strengthen cybersecurity and does not have any other impact on the software of the device?
Yes – Documentation / No – See Question 2
No
No changes to Software
2
Is the change made solely to return the system into specification of the most recently cleared device?
Yes – Documentation / No – See Question 3a
No
No changes to Software
3a
Does the change introduce a new risk or modify an existing risk that could result in significant harm and that is not effectively mitigated in the most recently cleared device?
Yes – new 510k / No – See Question 3b
No
No changes to Software
3b
Does the change create or necessitate a new risk control measure or a modification of an existing risk control measure for a hazardous situation that could result in significant harm?
Yes – new 510k / No – See Question 4
No
No changes to Software
4
Could the change significantly affect clinical functionality or performance specifications that are directly associated with the intended use of the device?
Yes – new 510k / No – Evaluate Section VI
No
No changes to Software
Section VI
Infrastructure - Does this introduce modifications made to the software support system?
(examples of insignificant/significant changes in guidance)
No
No changes to Software
Section VI
Architecture - Does this introduce modifications to the overall structure of the software?
(examples of insignificant/significant changes in guidance)
No
No changes to Software
Section VI
Core algorithm - Does this introduce modifications made to an algorithm that directly impact or contribute to the device’s intended use?
(examples of insignificant/significant changes in guidance)
No
No changes to Software
Section VI
Clarification of Requirements – No Change to Functionality - Does the change clarify software requirements after a product has received premarket clearance?
(examples of insignificant/significant changes in guidance)
No
No changes to Software
Section VI
Cosmetic Changes – No Change to Functionality – Is this a change to the appearance of the device that does not impact the clinical use of the device?
(examples of insignificant/significant changes in guidance)
No
No changes to Software
Section VI
Reengineering and refactoring - Does this change:
Examine and alter software to reconstitute it in a new form, and includes the subsequent implementation of the new form?
Restructure the software program’s internal structure without changing its clinical performance specification.
(examples of insignificant/significant changes in guidance)
No
No changes to Software
Section VI
Additional Software Changes not addressed in Guidance Section VI shall be documented below:
No
No changes to Software
END OF DEVICE SOFTWARE CHANGE DECISION MATRIX